What’s the current market cap for Ovid Therapeutics stock?

Ovid Therapeutics (OVID) has a market cap of $422M as of May 22, 2026.

What is the P/E ratio for Ovid Therapeutics stock?

The price to earnings (P/E) ratio for Ovid Therapeutics (OVID) stock is 0 as of May 22, 2026.

Does Ovid Therapeutics stock pay dividends?

No, Ovid Therapeutics (OVID) stock does not pay dividends to its shareholders as of May 22, 2026.

When is the next Ovid Therapeutics dividend payment date?

Ovid Therapeutics (OVID) stock does not pay dividends to its shareholders.

What is the beta indicator for Ovid Therapeutics?

Ovid Therapeutics (OVID) does not currently have a Beta indicator.

Buy Ovid Therapeutics stock | $OVID Share Price

About Ovid Therapeutics

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ticker

$OVID

Sector

Health

Primary listing

NASDAQ

Employees

23

Headquarters

New York, United States

Website

www.ovidrx.com

OVID Metrics

BasicAdvanced

$422m

-

-$0.27

-

What the Analysts think about OVID

Analyst ratings (Buy, Hold, Sell) for Ovid Therapeutics stock.

Bulls say / Bears say

Ovid ended 2025 with $90.4 million in cash, equivalents, and marketable securities, and could raise up to $53.9 million more if all Series A warrants are exercised—potentially extending its cash runway into 2029 (GlobeNewswire)

Phase 1 data for OV329 showed a favorable safety, tolerability, and pharmacokinetic profile at 5 mg and 7 mg doses, supporting dose flexibility and the planned Phase 2 proof-of-concept and dose-confirmatory studies in drug-resistant epilepsies (GlobeNewswire)

Ovid achieved the first clinical validation of direct KCC2 activation with positive Phase 1 results for OV350 and received clearance for OV4071 Phase 1, positioning it as a pioneer in a new mechanism for seizure and neuropsychiatric disorders (GlobeNewswire)

The company is advancing a differentiated GABA-aminotransferase inhibitor program with OV329 and a proprietary KCC2 direct activator portfolio across multiple CNS indications, supporting a robust pipeline of first-in-class and next-generation candidates (GlobeNewswire)

Ovid reported a full-year net loss of $17.4 million for 2025 despite a Q4 net income, highlighting ongoing unprofitability outside of one-time gains and continued dependence on outside financing (GlobeNewswire)

The Series A warrants will expire on April 17, 2026 if not exercised, creating a risk of dilution or underfunding if holders do not convert into the projected $53.9 million in gross proceeds (GlobeNewswire)

Key clinical milestones for OV329 and KCC2 activator programs are expected to start in Q2 2026 or later, meaning a lengthy wait for potential proof-of-concept data and significant regulatory risk in the meantime (GlobeNewswire)

Data summarised monthly by Lightyear AI. Last updated on 28 Apr 2026.

OVID Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

OVID Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

OVID News

AllArticlesVideos

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Benzinga·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Ovid Therapeutics

Ticker

Employees

OVID Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about OVID

Analyst Ratings

Bulls say / Bears say

OVID Financial Performance

Income Statement

OVID Earnings Performance

Earnings per share (EPS)

OVID News

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Buy $OVID

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Ovid Therapeutics/$OVID

About Ovid Therapeutics

Ticker

Employees

OVID Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about OVID

Analyst Ratings

Bulls say / Bears say

OVID Financial Performance

Income Statement

OVID Earnings Performance

Earnings per share (EPS)

OVID News

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Buy $OVID

Upcoming events

No upcoming events

What’s the current market cap for Ovid Therapeutics stock?

What is the P/E ratio for Ovid Therapeutics stock?

Does Ovid Therapeutics stock pay dividends?

When is the next Ovid Therapeutics dividend payment date?

What is the beta indicator for Ovid Therapeutics?

Bulls say / Bears say